He expects VAFSEO’s ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia. A biopharmaceutical team ...

Akebia Therapeutics' stock is down 28% after a proposed stock offering, with declining Auryxia revenues and significant financial challenges. Vafseo's market launch shows some promise, but it's a ...

Akebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia’s declining revenues from patent expiration. Vafseo is now approved for dialysis patients and leverages AKBA ...

Akebia to host conference call at 8:00 a.m. ET Vadadustat NDA assigned a PDUFA date of March 27, 2024 Vadadustat approved in 36 countries, including Australia and Taiwan Akebia strengthens cash ...

Auryxia is approved for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis and for the treatment of iron deficiency anemia in adult patients with ...

(RTTNews) - Akebia Therapeutics, Inc. (AKBA) Thursday announced positive results from its Phase 4 collaborative study, IMPACT, which examined the effects of Auryxia or ferric citrate as the ...

"We ended our year delivering on our strategic focus, which included a commitment to maximize Auryxia revenue, support vadadustat globally and thoughtfully invest in our pipeline," said John P.

The Centers for Disease Control and Prevention (CDC) has issued guidance for healthcare facilities in response to the COVID-19 virus including asking all U.S. healthcare facilities to “explore ...

Akebia Therapeutics has filed a lawsuit against CMS for rescinding Medicare Part D coverage of the company’s FDA-approved iron drug Auryxia and for the agency’s decision to impose a prior ...